News and Announcements
SUDA Invited To Northern Australia Investment Forum
- Published November 04, 2015 4:35PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
3rd November 2015, ASX Announcement
SUDA Ltd (ASX:SUD), a leader in oro-mucosal drug delivery, today announces that Mr. Stephen Carter, Chief Executive Officer and Managing Director, has been invited by Hon. Andrew Robb, Minister for Trade and Investment, to attend the Northern Australia Investment Forum, being held in Darwin, Australia from 8 to 10 November 2015.
The forum is a high-level, invitation-only event. The Minister has invited senior executives from leading international companies and global health philanthropies who are interested to understand better the diversity and scale of Australian research into tropical diseases. Mr. Carter has been invited to promote investment opportunities regarding SUDA’s novel anti-malarial sublingual spray, ArTiMistTM.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
